The short version of thymosin alpha 1 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
=== Psychiatry === Suvorexant has been studied in the treatment of insomnia in people with psychiatric disorders such as depression and anxiety. It was reported to improve psychiatric symptoms and to decrease cortisol levels in these individuals. A phase IV clinical trial of suvorexant as an adjunct to antidepressant therapy in people with major depressive disorder and residual insomnia was underway as of 2019. Although orexin receptor antagonists including suvorexant could be useful for treatment of depression and anxiety, there is also indication that they could have harmful effects in these conditions (e.g., animal studies and suicidal ideation in clinical trials). More clinical research is needed to determine the place of orexin receptor antagonists in the treatment of people with depression and anxiety. There is interest in suvorexant and other orexin receptor antagonists in the potential treatment of substance use disorders, including alcohol use disorder, cocaine use disorder, and opioid use disorder.
=== Cell membrane === The urothelium is the most impermeable membrane in the mammalian body. Because of its importance in acting as an osmotic barrier between the contents of the urinary tract and the surrounding organs and tissues, transitional epithelium is relatively impermeable to water and salts. This impermeability is due to a highly keratinized cellular membrane synthesized in the Golgi apparatus. The membrane is made up of a hexagonal lattice put together in the Golgi apparatus and implanted into the surface of the cell by reverse pinocytosis, a type of exocytosis. The cells in the superficial layer of the transitional epithelium are highly differentiated, allowing for maintenance of this barrier membrane. The basal layer of the epithelium is much less differentiated; however, it does act as a replacement source for more superficial layer. While the Golgi complex is much less prominent in the cells of the basal layer, these cells are rich in cytoplasmic proteins that bundle together to form tonofibrils. These tonofibrils converge at hemidesmosomes to attach the cells at the basement membrane.
Cholesterol synthesis: The cytosolic acetyl-CoA can also condense with acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) which is the rate-limiting step controlling the synthesis of cholesterol. Cholesterol can be used as is, as a structural component of cellular membranes, or it can be used to synthesize steroid hormones, bile salts, and vitamin D. Other biosynthetic roles: Acetyl-CoA can be carboxylated in the cytosol by acetyl-CoA carboxylase, giving rise to malonyl-CoA, a substrate required for synthesis of flavonoids and related polyketides, for elongation of fatty acids to produce waxes, cuticle, and seed oils in members of the Brassica family, and for malonation of proteins and other phytochemicals. In plants, these include sesquiterpenes, brassinosteroids (hormones), and membrane sterols. Steroid synthesis: Acetyl-CoA participates in the mevalonate pathway by partaking in the synthesis of hydroxymethyl glutaryl-CoA. Acetylcholine synthesis: Acetyl-CoA is also an important component in the biogenic synthesis of the neurotransmitter acetylcholine. Choline, in combination with acetyl-CoA, is catalyzed by the enzyme choline acetyltransferase to produce acetylcholine and coenzyme A as a byproduct. Melatonin synthesis Acetylation: Acetyl-CoA is also the source of the acetyl group incorporated onto certain lysine residues of histone and nonhistone proteins in the posttranslational modification acetylation. This acetylation is catalyzed by acetyltransferases. This acetylation affects cell growth, mitosis, and apoptosis.
The Stuart Patton Auditorium in the Agricultural Sciences and Industries Building at Penn State is dedicated in his honor “for his inquisitive nature and skill in imparting knowledge; for his enthusiasm for science and uncompromising respect for peers.” In 2018, Dr. Patton's colleague, Ian H. Mather, added this touching tribute to Patton in his article in the Journal of Dairy Science: "This review is dedicated to the memory of Stuart Patton (1920–2017), Evan Pugh Professor Emeritus, Pennsylvania State University, and colleague, friend, and unofficial mentor of the senior author (IHM). The footprints of Dr. Patton’s research are evident throughout the pages of this review" (article is Symposium Review: Intravital imaging of the lactating mammary gland in live mice reveals novel aspects of milk-lipid secretion In a letter submitted in support of Patton's nomination as a fellow of the American Dairy Science Association in 2001, Dr. Ian Maher stated the following, "Dr. Patton's research is characterized by careful attention to experimental detail and a thorough knowledge of the literature. The discussion sections of his papers are always brimming with ideas, thought provoking and creative. A consistent feature of the work is novelty, whether it is a simple solution to a practical problem, or an inspirational idea that leads to new avenues of research. An example of the former is the simple but elegant method Dr. Patton devised to separate milk-fat globules from skim-milk components in a single step by density gradient centrifugation (Patton, S., and Huston, G.E.
Sources: en.wikipedia.org
== References == Hunter, R. L.; Merkert, C.L. (1957). "Histochemical demonstration of enzymes separated by zone electrophoresis in starch gels". Science. 125 (3261): 1294–1295. doi:10.1126/science.125.3261.1294-a. PMID 13432800. Weiss, B.; Hait, W.N. (1977). "Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents". Annu. Rev. Pharmacol. Toxicol. 17: 441–477. doi:10.1146/annurev.pa.17.040177.002301. PMID 17360. Wendel, JF, and NF Weeden. 1990. "Visualisation and interpretation of plant isozymes." pp. 5–45 in D. E. Soltis and P. S. Soltis, eds. Isozymes in plant biology. Chapman and Hall, London. Weeden, NF, and JF Wendel. 1990. "Genetics of plant isozymes". pp. 46–72 in D. E. Soltis and P. S. Soltis, eds. Isozymes in plant biology. Chapman and Hall, London Crawford, DJ. 1989. "Enzyme electrophoresis and plant systematics". pp. 146–164 in D. E. Soltis and P. S. Soltis, eds. Isozymes in plant biology. Dioscorides, Portland, Oregon. Hamrick, JL, and MJW Godt. 1990. "Allozyme diversity in plant species". pp. 43–63 in A. H. D. Brown, M. T. Clegg, A. L. Kahler and B. S. Weir, eds. Plant Population Genetics, Breeding, and Genetic Resources. Sinauer, Sunderland Biochemistry by jeremy M. Berg, John L. Tymoczko, Lubert Stryer (Intro taken from this textbook) Specific
=== Canada === In 2026, cottage cheese consumption increased by 15-20% over market levels in recent years, causing a supply shortage in some regions. In 2025, 35,459 tonnes (78,174,000 lb) of cottage cheese were produced in Canada. The Canadian Dairy Commission maintains consumer guidelines and standards for quality manufacturing of cottage cheese.
Foods (fava beans is the hallmark trigger for G6PD mutation carriers) Certain medicines including rasburicase, primaquine and other antimalarials[PMID 36049896] Moth balls (naphthalene) Stress from a bacterial or viral infection
Many complexes are known with cyclopropenium ligands. Examples include [M(C3Ph3)(PPh3)2]+ (M = Ni, Pd, Pt) and Co(C3Ph3)(CO)3. Such compounds are prepared by reaction of cyclopropenium salts with low valent metal complexes.
Culver's soon shifted its attention to developing markets beyond the Midwest, and opened the first franchise outside the region in Texas in February 1998. The current franchising strategy is one of strategic expansion. The chain expanded into Colorado Springs, Colorado and Cheyenne, Wyoming in 2005, followed by an opening in Bowling Green, Kentucky in July 2006. Locations traditionally had a 120-seat format through much of Culver's expansion. The Metro-98 prototype was developed in 2006 and first constructed in Fort Dodge, Iowa. While the new layout has less seating to offer guests, it also reduced the amount of land needed for construction by around 20%. The company expanded to the Phoenix metropolitan area in 2008. The first franchise in Utah opened in Midvale in 2011, when a couple from Wisconsin relocated there. They signed a development agreement for four locations in the southern half of Salt Lake County. By the end of 2011, 445 Culver's restaurants were open in 19 states. They opened in South Carolina in 2012; Florida, Georgia, and Tennessee in 2014; and North Carolina in 2015. A location was announced for Alabama in June 2018, and expansion continued into Arkansas in January 2022. In February 2026, Culver's announced plans to enter the Virginia market, starting with their first location in the Richmond area.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.